Your browser doesn't support javascript.
loading
Cost-effectiveness of prophylaxis with recombinant vs plasma-derived VWF in severe von Willebrand disease in the United States.
Waldron, Christina; Ito, Satoko; Wang, Daniel; Allen, Cecily; Viswanathan, Giri; Bona, Robert D; Cuker, Adam; Goshua, George.
Afiliação
  • Waldron C; Yale School of Medicine, New Haven, CT.
  • Ito S; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
  • Wang D; Yale School of Medicine, New Haven, CT.
  • Allen C; Division of Hematology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD.
  • Viswanathan G; Yale College, New Haven, CT.
  • Bona RD; Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
  • Cuker A; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Goshua G; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Blood ; 143(22): 2332-2335, 2024 May 30.
Article em En | MEDLINE | ID: mdl-38635764
ABSTRACT
ABSTRACT We evaluated the cost-effectiveness of prophylaxis with recombinant von Willebrand factor (rVWF) vs with plasma-derived von Willebrand factor (pdVWF) for patients with severe Von Willebrand disease. We found that rVWF is a cost-saving factor replacement compared with pdVWF across all willingness-to-pay thresholds in the United States.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças de von Willebrand / Proteínas Recombinantes / Fator de von Willebrand / Análise Custo-Benefício Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças de von Willebrand / Proteínas Recombinantes / Fator de von Willebrand / Análise Custo-Benefício Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article